The calcium-binding protein S100P in normal and malignant human tissues

Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.
BMC Clinical Pathology 02/2008; 8(1):2. DOI: 10.1186/1472-6890-8-2
Source: PubMed


S100P is a Ca2+ binding protein overexpressed in a variety of cancers, and thus, has been considered a potential tumor biomarker. Very little has been studied about its normal expression and functions.
We examined S100P expression in normal human tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. S100P protein expression was also studied in a series of tumors, consisting of 74 ovarian, 11 pancreatic, 56 gastric, 57 colorectal, 89 breast and 193 prostate carcinomas using a novel anti-S100P monoclonal antibody.
Among the normal tissues, the highest S100P mRNA levels were observed in the placenta and esophagus. Moderate signals were also detected in the stomach, duodenum, large intestine, prostate and leukocytes. At the protein level, the highest reactions for S100P were seen in the placenta and stomach. Immunostaining of tumor specimens showed that S100P protein is expressed in all the tumor categories included in the study, being most prevalent in gastric tumors.
Based on our observations, S100P is widely expressed in both normal and malignant tissues. The high expression in some tumors suggests that it may represent a potential target molecule for future diagnostic and therapeutic applications.

Download full-text


Available from: Seppo Parkkila,
17 Reads
  • Source
    • "Nuclear, cytoplasmic, or membrane localization has been recognized in different experimental settings [7] [10]. Parkkila et al. [7] showed strong nuclear staining in breast carcinoma sections, with some apparently cytoplasmic staining also present similar to our observation in Fig. 3E. Maciejczyk et al. [6] reported nuclear staining in 73% of breast cancers and cytoplasmic staining in 69% (the majority classified as borderline or weak). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The calcium-binding protein S100P is overexpressed in various cancers and may contribute to the oncogenic phenotype. This study used mass spectrometry to characterize a novel 9.2-kDa C-terminally truncated form of S100P (t-S100P), and to investigate its potential prognostic value in breast cancer. Univariate analysis demonstrated the association between breast tissue t-S100P levels (n = 148) and conventional pathological markers. Across all tumor samples, high t-S100P was strongly prognostic for poor disease-free survival (P = 0.005), its efficacy confined to lymph node-positive tumors (n = 74, P = 0.007). Matrix-assisted laser desorption/ionization imaging mass spectrometry confirmed differential t-S100P abundance between breast cancer and unaffected adjacent tissue. t-S100P was exclusively located in the cell nucleus of breast cancer tissue, and full-length S100P was essentially undetectable by mass spectrometry. We conclude that t-S100P is the predominant form of S100P in breast cancer tissue and is strongly prognostic for disease-free survival in women with lymph node-positive disease. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Cancer letters 08/2015; 368(1). DOI:10.1016/j.canlet.2015.07.046 · 5.62 Impact Factor
    • "c o m / l o c a t e / y e x m p angiogenesis, cytoskeleton interactions, protein phosphorylation, regulation of transcriptional factors, autoimmunity, chemotaxis, inflammation and pluripotency and metastasis (Chen et al., 2014; Arumugam et al., 2004; Wang et al., 2006). Overexpression of S100P has been reported in many cancers (Parkkila et al., 2008; Jiang et al., 2012). Several studies have investigated S100P in the carcinogenesis and development of breast cancer (Guerreiro Da Silva et al., 2000; Schor et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Triple-negative breast cancer (TNBC) is a group of very aggressive breast tumours, characterized by lack of expression of oestrogen receptor (ER), progesterone receptor (PR) and erb-b2 receptor tyrosine kinase 2 (ERBB2/HER2). Nevertheless, TNBCs show different clinical characteristics and are very diverse regarding prognostic outcome. So far, only a few prognostic markers for TNBC have been reported that could be helpful for therapeutic stratification. Here we have analysed the expression of S100P and HYAL2 using immunohistochemistry (IHC) in a TNBC cohort of 98 patients with a follow-up for recurrence and death. TNBC patients with high expression of both proteins showed significantly shorter progression-free survival (PFS) (mean PFS = 35.9 months, P = 0.001) compared to TNBC patients with high expression levels of only one of the proteins (mean PFS = 69.4 months) and to TNBC patients with low expression of both proteins (mean PFS = 83.3 months). Moreover, multivariate Cox-regression model showed the combined expression of S100P and HYAL2 as independent prognostic factor for PFS (P = 0.001). The expression of S100P and HYAL2 indicated similar prognostic effect to the overall survival (OS) of TNBC patients. In addition, high expression levels of both S100P and HYAL2 showed significant association with different clinicopathological characteristics, such as more recurrence events (P = 0.004), and higher occurrence of metastasis (P = 0.002). Our study proposes S100P and HYAL2 as potential prognostic markers for TNBC. Copyright © 2015. Published by Elsevier Inc.
    Experimental and Molecular Pathology 06/2015; 99(1). DOI:10.1016/j.yexmp.2015.06.010 · 2.71 Impact Factor
  • Source
    • "A few of these genes seemed to be particularly interesting. For example, S100P calcium binding protein (which expression is regulated by androgens and IL6 – another up-regulated gene in the most malignant canine mammary tumours) is though as a new prognostic factor (Parkkila et al. 2008). A correlation was found between its increased expression and poor survival, cancer proliferation and increased resistance to chemotherapy (Maciejczyk et al. 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Because canine mammary tumours constitute a serious clinical problem and there are no good prognostic markers (only histopathological variables are used), the aim of the presented study was to find new malignancy markers as well as to identify intracellular pathways and biological processes characteristic for canine mammary malignancy. We compared gene expression of the most malignant mammary tumours (poorly differentiated cancers of the 3rd grade of malignancy) with less malignant tumours (well differentiated cancers of the 1st grade of malignancy). The results of our study indicated that in dogs the number of tumour-infiltrating myeloid cells or expression of myeloid-specific antigens by cancer cells is related to the cancer progression and may constitute a new marker of malignancy, however further studies in this field are required.
    Veterinary Research Communications 02/2013; 37(2). DOI:10.1007/s11259-013-9554-1 · 1.24 Impact Factor
Show more